Seattle Genetics has announced top-line results from a phase II trial of its antibody-drug conjugate (ADC) brentuximab vedotin (SGN-35) for patients with relapsed or refractory Hodgkin's lymphoma.
According to the announcement, 75 percent of the patients achieved an objective response, and the median duration of this response was more than six months. Seattle Genetics will present a more complete picture of the data from this trial at an upcoming hematology/oncology meeting.
The company also announced that they would have top-line results from another phase II trial of brentuximab vedotin for patients with anaplastic large cell lymphoma "within the next few weeks."
CANCER TYPE(S)
Hodgkin's lymphoma
TREATMENT TYPE(S)
Antibody-drug conjugate
Source
Seattle Genetics
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
